title: [Melanoma: a new therapeutic era].
abstract: Melanoma is the cancer with the fastest incidence increase in Switzerland. 30% of the cases arise before the age of 50 years. Once metastatic, the median survival under current systemic therapies is about 8 months, with less than 5% of patients alive at 5 years. Many efforts in the understanding of cellular biology, intracellular signaling pathways, as well as the role of cellular immunity have been made in the recent years. This has resulted in the development of novel and very promising therapies. In this review, we will cover the results obtained with targeted therapies such as "tyrosin kinase inhibitors" (TKI), as well as those obtained with a monoclonal antibody directed against the CTLA-4 receptor of lymphocytes.
authors: Centre pluridisciplinaire d'oncologie, CHUV, Lausanne. gregoire.berthod@chuv.ch
authors: G
authors: G
authors: Berthod
authors: K
authors: K
authors: Homicsko
authors: H
authors: H
authors: Bouchaab
authors: M
authors: M
authors: Matter
authors: J-P
authors: JP
authors: Cerottini
authors: D
authors: D
authors: Guggisberg
authors: D
authors: D
authors: Speiser
authors: S
authors: S
authors: Leyvraz
authors: O
authors: O
authors: Michielin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000187:drug effects*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D060908:CTLA-4 Antigen; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D008545:Melanoma / Q000188:drug therapy* / Q000453:epidemiology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D015996:Survival Rate; D013557:Switzerland / Q000453:epidemiology
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D011505:Protein-Tyrosine Kinases